Oral effects of low-dose methotrexate treatment

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 100, Issue 1, 2005, Pages 52-62

  Kalantzis, Athanasios ^a,d   Marshman, Zoe ^b   Falconer, Denis T ^c   Morgan, Peter R ^a   Odell, Edward W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c OLDCHURCH HOSPITAL   (United Kingdom)

^d LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ABDOMINAL DISCOMFORT; ANOREXIA; ATHEROMA; BONE MARROW SUPPRESSION; CONFUSION; DENTIST; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG MECHANISM; DYSPEPSIA; FATIGUE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERHOMOCYSTEINEMIA; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG TOXICITY; LYMPHOMA; MEDICAL LITERATURE; MOUTH ULCER; NAUSEA; OSTEOPOROSIS; PANCYTOPENIA; PNEUMOCYSTOSIS; REVIEW; STOMATITIS; STRESS FRACTURE; TASTE DISORDER; TREATMENT INDICATION; VOMITING; WEIGHT REDUCTION;

EID: 20444490302     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2004.08.020     Document Type: Article

References (94)

1. G.S. Alarcon Methotrexate use in rheumatoid arthritis. A Clinician's perspective Immunopharmacology 47 2000 259 271
2. B. Bannwarth, F. Pehourcq, T. Schaeverbeke, and J. Dehais Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis Clin Pharmacokinet 30 1996 194 210
3. M.E. Suarez-Almazor, E. Belseck, B. Shea, G. Wells, and P. Tugwell Methotrexate for rheumatoid arthritis Cochrane Database Sys Rev 2 2000 CD000957
4. A. Schnabel, and W.L. Gross Low-dose methotrexate in rheumatic diseases - efficacy, side effects, and risk factors for side effects Semin Arthritis Rheum 5 1994 310 327
5. M.E. Weinblatt, D.E. Trentham, P.A. Fraser, D.E. Holdsworth, K.R. Falchuk, and B.N. Weissman Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis Arthritis Rheum 2 1988 167 175
6. E.H. Giannini, J.T. Cassidy, E.J. Brewer, A. Shaikov, A. Maximov, and N. Kuzmina Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis Semin Arthritis Rheum 1 1993 34 46
7. T. Takken, J. Van der Net, and P.J. Helders Methotrexate for treating juvenile idiopathic arthritis [update in Cochrane Database Syst Rev. 2001;(4):CD003129; PMID: 11687174] Cochrane Database Syst Rev 3 2001 CD003129
8. N.T. Ilowite Current treatment of juvenile rheumatoid arthritis Pediatrics 1 2002 109 115
9. U.F. Haustein, and M. Rytter Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment J Eur Acad Dermatol Venereol 5 2000 382 388
10. A.L. Kuijpers, and P.C. van de Kerkhof Risk-benefit assessment of methotrexate in the treatment of severe psoriasis Am J Clin Dermatol 1 2000 27 39
11. G. Jones, M. Crotty, and P. Brooks Interventions for psoriatic arthritis [update of Cochrane Database Syst Rev 2000;(2):CD000212; PMID: 10796328] Cochrane Database Syst Rev 3 2000 CD000212
12. M. Lemann, T. Zenjari, Y. Bouhnik, J. Cosnes, B. Mesnard, and J.C. Rambaud Methotrexate in Crohn's disease: long-term efficacy and toxicity Am J Gastroenterol 7 2000 1730 1734
13. A.G. Fraser, D. Morton, D. McGovern, S. Travis, and D.P. Jewell The efficacy of methotrexate for maintaining remission in inflammatory bowel disease Aliment Pharmacol Ther 4 2002 693 697
14. B.G. Feagan, R.N. Fedorak, E.J. Irvine, G. Wild, L. Sutherland, and A.H. Steinhart A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators N Engl J Med 22 2000 1627 1632
15. O. Kaye, E. Palazzo, M. Grossin, P. Bourgeois, M. Kahn, and M. Malaise Low-dose methotrexate: an effective corticosteriod-sparing agent in the musculoskeletal manifestations of sarcoidosis Br J Rheumatol 7 1995 642 644
16. M.G. Marin Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis [Comment] Chest 1 1997 29 33
17. Y. Koga, Y. Nagatoshi, Y. Kawano, and J Okamura Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan Bone Marrow Transplant 2 2003 171 176
18. S.D. Aaron, R.E. Dales, and B. Pham Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials Respir Med 92 1998 1059 1065
19. H. Davies, L. Olson, and P. Gibson Methotrexate as a steroid sparing agent for asthma in adults Cochrane Database Syst Rev 2002 CD000391
20. E.I. Sato Methotrexate therapy in systemic lupus erythematosus Lupus 3 2001 162 164
21. M.M. Seyger, F.H. van den Hoogen, I.M. van Vlijmen-Willems, P.C. van de Kerkhof, and E.M. de Jong Localized and systemic scleroderma show different histological responses to methotrexate therapy J Pathol 4 2001 511 516
22. J.S. Kasteler, and J.P. Callen Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis [Comment] J Am Acad Dermatol 1 1997 67 71
23. A. Lugaresi, C. Caporale, D. Farina, F. Marzoli, L. Bonanni, and P. Muraro Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis Neurol Sci 2 2001 209 210
24. S. Bom, P. Zamiri, and S. Lightman Use of methotrexate in the management of sight-threatening uveitis Ocul Immunol Inflamm 1 2001 35 40
25. G.S. Alarcon Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders W. Koopman Arthritis & allied conditions. A textbook of rheumatology 13th ed. 1997 Williams and Wilkins London 679 698
26. D.E. Furst Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis Br J Rheumatol 34 Suppl 2 1995 20 25
27. A.E. van Ede, R.F. Laan, H.J. Blom, R.A. De Abreu, and L.B. van de Putte Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity Semin Arthritis Rheum 5 1998 277 292
28. L. Genestier, R. Paillot, L. Quemeneur, K. Izeradjene, and J.P. Revillard Mechanisms of action of methotrexate Immunopharmacology 2-3 2000 247 257
29. B.F. Leeb, G. Witzmann, E. Ogris, A. Studnicka-Benke, I. Andel, and H. Schweitzer Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients Clin Exp Rheumatol 4 1995 459 463
30. M. Cutolo, A. Sulli, C. Pizzorni, B. Seriolo, and R.H. Straub Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis Ann Rheum Dis 8 2001 729 735
31. J.M. Kremer, and J.K. Lee A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months Arthritis Rheum 5 1988 577 584
32. W. Urano, A. Taniguchi, H. Yamanaka, E. Tanaka, H. Nakajima, and Y. Matsuda Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses Pharmacogenetics 3 2002 183 190
33. R.J. McKendry The remarkable spectrum of methotrexate toxicities Rheum Dis Clin North Am 4 1997 939 954
34. H. Mielants, E.M. Veys, C. Van der Straeten, C. Ackerman, and S. Goemaere The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study J Rheumatol 7 1991 978 983
35. J. Thumboo, W.H. Koh, K.H. Leong, M.L. Boey, and P.H. Feng The safety of weekly low dose oral methotrexate in an Oriental population with rheumatoid arthritis Ann Acad Med Singapore 2 1997 205 209
36. R.J. McKendry, and P. Dale Adverse effects of low dose methotrexate therapy in rheumatoid arthritis J Rheumatol 11 1993 1850 1856
37. F. Salaffi, M. Carotti, A. Sartini, and C. Cervini A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis Clin Exper Rheumatol 1 1995 23 28
38. C.S. Fehlauer, C.W. Carson, G.W. Cannon, J.R. Ward, C.O. Samuelson, and H.J. Williams Methotrexate therapy in rheumatoid arthritis: 2-year retrospective followup study J Rheumatol 3 1989 307 312
39. F. Wolfe, D.J. Hawley, and M.A. Cathey Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts J Rheumatol 8 1990 994 1002
40. H.J. Williams, R.F. Willkens, C.O. Samuelson Jr., G.S. Alarcon, M. Guttadauria, and C. Yarboro Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial Arthritis Rheum 7 1985 721 730
41. G.S. Alarcon, I.C. Tracy, and W.D. Blackburn Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment Arthritis Rheum 32 1989 671 676
42. J. Bauer, M. Fartasch, G. Schuler, and H. Schell [Ulcerative stomatitis as clinical clue to inadvertent methotrexate overdose.] Hautarzt 50 1999 670 673 German
43. Anonymous Low dose methotrexate therapy - toxic if not taken correctly. Adverse Drug Reactions Advisory Committee Med J Aust 161 1994 152
44. B.M. Lomaestro, T.S. Lesar, and T.P. Hager Errors in prescribing methotrexate JAMA 15 1992 2031 2032
45. P. Duhra Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis J Am Acad Dermatol 3 1993 466 469
46. J.M. Berthelot, Y. Maugars, M. Hamidou, A. Chiffoleau, J. Barrier, and J.Y. Grolleau Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) Rev Rhum Engl Ed 62 1995 477 486
47. D. Zisman, W. McCune, G. Tino, and J. Lynch Drug-induced pneumonitis: the role of methotrexate Sarcoidosis Vasc Diffuse Lung Dis 3 2001 243 252
48. H.A. Capell Disease modifying antirheumatic drugs: longterm safety issues J Rheumatol Suppl 62 2001 10 15
49. R. Westhovens, and J. Dequeker Rheumatoid arthritis and osteoporosis Z Rheumatol 59 Suppl 1 2000 33 38
50. N.J. Minaur, D. Kounali, S. Vedi, J.E. Compston, J.N. Beresford, and A.K. Bhalla Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density Rheumatology 7 2002 741 749
51. A.B. Cranney, R.J. McKendry, G.A. Wells, D.S. Ooi, N.D. Kanigsberg, and G.R. Kraag The effect of low dose methotrexate on bone density J Rheumatol 11 2001 2395 2399
52. A.M. Boerbooms, P.J. Kerstens, J.W. van Loenhout, J. Mulder, and L.B. van de Putte Infections during low-dose methotrexate treatment in rheumatoid arthritis Semin Arthritis Rheum 24 1995 411 421
53. K.S. Kanik, and J.M. Cash Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin North Am 4 1997 955 967
54. P.G. Conaghan, D.I. Quinn, P.M. Brooks, and R.O. Day Hazards of low dose methotrexate Aust N Z J Med 6 1995 670 673
55. P. Beauparlant, K. Papp, and B. Haraoui The incidence of cancer associated with the treatment of rheumatoid arthritis Semin Arthritis Rheum 29 1999 148 158
56. J. Sibilia, F. Liote, and X. Mariette Lymphoproliferative disorders in rheumatoid arthritis patients on low-dose methotrexate Rev Rhum Engl Ed 4 1998 267 273
57. D.E. Furst, N. Erikson, L. Clute, R. Koehnke, L.F. Burmeister, and J.A. Kohler Adverse experience with methotrexate during 176 weeks of a long-term prospective trial in patients with rheumatoid arthritis J Rheumatol 12 1990 1628 1635
58. I. Getov, Z. Dimitrova, and V. Petkova Low dose treatment with methotrexate-adverse drug reactions survey Boll Chim Farm 4 2000 153 158
59. A. Schnabel, E. Reinhold-Keller, V. Willmann, and W.L. Gross Side effects of 15mg and 25mg methotrexate/week for rheumatoid arthritis Arthritis Rheum 5 1992 146
60. E. Ishii, S. Yamada, S. Higuchi, T. Honjo, H. Igarashi, and S. Kanemitsu Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia Med Pediatr Oncol 5 1989 429 432
61. J. Press, M. Berkovitch, R. Laxer, E. Giesbrecht, Z. Verjee, and E. Silverman Evaluation of therapeutic drug monitoring of methotrexate in saliva of children with rheumatic diseases Ther Drug Monit 3 1995 247 250
62. C. Rask, F. Albertioni, H. Schroder, and C. Peterson Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate Pediatr Hematol Oncol 4 1996 359 367
63. F. Albertioni, C. Rask, H. Schroeder, and C. Peterson Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis Anticancer Drugs 2 1997 119 124
64. G. Dahllof, A. Heimdahl, T. Modeer, S. Twetman, P. Bolme, and O. Ringden Oral mucous membrane lesions in children treated with bone marrow transplantation Scand J Dent Res 3 1989 268 277
65. S. Dreizen, B.M. Levy, and S. Bernick Studies on the biology of the periodontium of marmosets: 8. The effect of folic acid deficiency on the marmoset oral mucosa J Dent Res 3 1970 616 620
66. N. Yoshinari, Y. Kameyama, Y. Aoyama, H. Nishiyama, and T. Noguchi Effect of long-term methotrexate-induced neutropenia on experimental periodontal lesion in rats J Periodontal Res 6 1994 393 400
67. G.K. Endresen, and G. Husby Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines Scand J Rheumatol 3 2001 129 134
68. Z. Ortiz, B. Shea, M. Suarez Almazor, D. Moher, G. Wells, and P. Tugwell Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis Cochrane Database Syst Rev 2 2000 CD000951
69. D. Mitchell, P. Spitz, D. Young, D. Bloch, D. McShane, and J. Fries Survival, prognosis and causes of death in rheumatoid arthritis Arthritis Rheum 29 1986 706 714
70. D.S. Pisetsky, and E.W. St Clair Progress in the treatment of rheumatoid arthritis JAMA 22 2001 2787 2790
71. M. Luis, C. Pacheco-Tena, J. Cazarin-Barrientos, L. Lino-Perez, M.V. Goycochea, and J. Vazquez-Mellado Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study Arthritis Rheum 10 1999 2160 2165
72. D.T. Felson, J.J. Anderson, and R.F. Meenan Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials Arthritis Rheum 10 1992 1117 1125
73. R.J. McKendry, and M. Cyr Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients Arch Intern Med 3 1989 685 689
74. A. Maetzel, A. Wong, V. Strand, P. Tugwell, G. Wells, and C. Bombardier Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs Rheumatology 9 2000 975 981
75. D.L. Scott Advances in the medical management of rheumatoid arthritis Hosp Med 5 2002 294 297
76. J.M. Kremer Rational use of new and existing disease-modifying agents in rheumatoid arthritis Ann Int Med 8 2001 695 706
77. H. Klaus Quantitative criteria of folate deficiency in cervico-vaginal cytograms, with report of a new parameter Acta Cytol 1 1971 50 53
78. N. Whitehead, F. Reyner, and J. Lindenbaum Megaloblastic changes in cervical epithelium. Association with oral contraceptive therapy and reversal with folic acid JAMA 226 1973 1421 1424
79. L.G. Koss Diagnosis and early endometrial cancer and precancerous states Ann Clin Lab Sci 3 1979 189 194
80. P. Valente, G. Fassina, A. Melchiori, L. Masiello, M. Cilli, and A. Vacca TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis Int J Cancer 2 1998 246 253
81. N. Titenko-Holland, R. Jacob, N. Shang, A. Balaraman, and M. Smith Micronuclei in lymphocytes and exfoliated buccal cells of postmenopausal women with dietary changes in folate Mutat Res 417 1998 101 114
82. D.C. Heimburger Localized deficiencies of folic acid in aerodigestive tissues Ann N Y Acad Sci 669 1992 87 95
83. G.L. Hays Nuclear characteristics of buccal mucosa cells in sickle-cell anemia Oral Surg Oral Med Oral Pathol 43 1977 554 561
84. W.H. Westra, G.F. Holmes, and D.W. Eisle Bizarre epithelial atypia of the sinonasal tract Am J Surg Pathol 25 2001 652 656
85. X. Mariette, D. Cazals-Hatem, J. Warszawki, F. Liote, N. Balandraud, and J. Sibilia Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France Blood 99 2002 3909 3915
86. K.G. Moder, A. Tefferi, M.D. Cohen, D.M. Menke, and H.S. Luthra Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study Am J Med 99 3 1995 276 281
87. O.W. Kamel, M. van de Rijn, M.M. Hanasono, and R.A. Warnke Immunosuppression-associated lymphoproliferative disorders in rheumatic patients Leuk Lymphoma 16 5-6 1995 363 368
88. J.B. Shiroky, and M.M. Newkirk Reversible lymphomas N Engl J Med 329 22 1993 1657 1658
89. L. Georgescu, and S.A. Paget Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? Drug Safety 20 6 1999 475 487
90. Bulletin Board of Oral Pathology. Available at: http://www.sdm.buffalo. edu/bbop/. Accessed December 1, 2004.
91. K. Steinsson, A. Weinstein, J. Korn, and M. Abeles Low dose methotrexate in rheumatoid arthritis J Rheumatol 9 1982 860 866
92. R.M. Michaels, D.J. Nashel, A. Leonard, A.J. Sliwinski, and S.J. Derbes Weekly intravenous methotrexate in the treatment of rheumatoid arthritis Arthritis Rheum 25 1982 339 341
93. R.N. Thompson, C. Watts, J. Edelman, J. Esdaile, and A.S. Russell A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis J Rheumatol 11 1984 760 763
94. A. Weinstein, S. Marlowe, J. Korn, and F. Farouhar Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations Am J Med 79 1985 331 337